Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Operating Leases (2019 - 2025)

Sanofi (SNY) has disclosed Operating Leases for 7 consecutive years, with $2.0 billion as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 15.16% to $2.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Dec 2025, up 15.16% year-over-year, with the annual reading at $2.0 billion for FY2025, 10.35% up from the prior year.
  • Operating Leases hit $2.0 billion in Q4 2025 for Sanofi, up from $1.8 billion in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.2 billion in Q4 2023 to a low of $1.8 billion in Q4 2024.
  • Historically, Operating Leases has averaged $2.0 billion across 5 years, with a median of $2.0 billion in 2025.
  • Biggest five-year swings in Operating Leases: dropped 19.52% in 2024 and later rose 15.16% in 2025.
  • Year by year, Operating Leases stood at $2.1 billion in 2021, then fell by 7.66% to $1.9 billion in 2022, then rose by 12.44% to $2.2 billion in 2023, then fell by 19.52% to $1.8 billion in 2024, then grew by 15.16% to $2.0 billion in 2025.
  • Business Quant data shows Operating Leases for SNY at $2.0 billion in Q4 2025, $1.8 billion in Q4 2024, and $2.2 billion in Q4 2023.